Has Apotex Received US FDA Approval for Ruxolitinib?
No, Apotex has not received official US FDA approval for its ruxolitinib product as of the latest available data. The company filed an Abbreviated New Drug Application (ANDA) for ruxolitinib phosphate topical cream (ANDA 217871) targeting Incyte's Opzelura, but the FDA issued a Complete Response Letter (CRL) in late 2023 citing manufacturing deficiencies at a third-party site.[1] No approval has followed, and Apotex has not publicly announced resolution or resubmission success.
What is the Status of Apotex's ANDA?
Apotex's ANDA 217871 remains unapproved post-CRL. The FDA's Orange Book lists no Apotex ruxolitinib entries under Paragraph IV challenges or tentative approvals for topical or oral forms.[2] Oral ruxolitinib generics (targeting Jakafi) face active patent litigation, with Incyte defending until at least 2031 extensions.
When Might Apotex Launch a Ruxolitinib Generic?
Launch depends on FDA approval and patent settlements. Topical approval could occur after site reinspection, potentially in 2025 if resolved. Oral generics face hurdles: Jakafi patents expire 2027-2031, with 17 ANDAs pending Paragraph IV suits.[3] Apotex is among challengers but trails leaders like Taro and Sandoz.
Key Ruxolitinib Patents and Expiry Dates
| Product | Brand | Key Patents | Expiry |
|--------|-------|-------------|--------|
| Oral (Jakafi) | Incyte | US 7,598,257 (composition); US 8,415,366 (method) | 2027-2031 (pediatric extensions) [4] |
| Topical Cream (Opzelura) | Incyte | US 10,561,594 (topical formulation) | 2036 [4] |
Check DrugPatentWatch.com for litigation updates and full expiry timelines.
Competitors Approved or Close to Ruxolitinib Generics?
No generics approved yet. Taro, Dr. Reddy's, and Sandoz have tentative approvals for oral Jakafi ANDAs but await patent outcomes. Topical has zero ANDA approvals; Sun Pharma and others trail Apotex in filings.[3]
What Delays Generic Ruxolitinib Entry?
Manufacturing CRLs (as with Apotex), complex JAK inhibitor stability, and Incyte's 180-day exclusivity claims block at-risk launches. Patients report high Jakafi costs ($6,000+/month), driving demand, but litigation risks fines.[1][4]
Sources
[1]: FDA CRL Notice via Drugs.com
[2]: FDA Orange Book
[3]: FDA Paragraph IV Database
[4]: DrugPatentWatch.com - Ruxolitinib Patents